Epithelioid type angiomyolipoma is a rare tumor that usually starts in the kidney and can sometimes behave like a cancer. Many living with epithelioid type angiomyolipoma have no symptoms at first, but early symptoms of epithelioid type angiomyolipoma can include flank pain, blood in the urine, or a growing mass in the abdomen. It is most often found in adults, and some cases are linked to tuberous sclerosis complex. Not everyone will have the same experience, but this condition may stay stable or may grow and spread, so the outlook depends on the size, location, and how aggressive the tumor is. Treatment often involves surgery, and some people may also need close imaging follow-up or other cancer-style treatments if the tumor has spread.
How many people live with Epithelioid type angiomyolipoma?
There is no direct worldwide count for epithelioid type angiomyolipoma, but reports suggest kidney angiomyolipoma as a whole is found in about 0.13% of adults, and the epithelioid type may make up roughly 5% to 8% of those tumors; using current world population totals, that suggests about 530,000 to 850,000 people worldwide are living with the epithelioid type, and this is an estimate rather than a direct count (Fittschen et al., 2014; Nese et al., 2011; United Nations, 2024). Using the same method, the United States is estimated to have about 22,000 to 35,000 people living with this subtype, again as an estimate rather than a direct count (Fittschen et al., 2014; Nese et al., 2011; U.S. Census Bureau, 2024).
Overview
Epithelioid type angiomyolipomaSymptoms
Epithelioid type angiomyolipoma often causes no symptoms at first. When symptoms happen, people may notice belly or side pain, blood in the urine, a growing lump, or signs of bleeding such as sudden weakness or dizziness.
Outlook and prognosis
The outlook for epithelioid type angiomyolipoma varies because some tumors behave quietly while others can grow back or spread. Prognosis is often better when it is found early, fully removed, and followed closely with scans and specialist care.
Causes and risk factors
Epithelioid type angiomyolipoma often develops because of changes in TSC genes, either inherited through tuberous sclerosis complex or happening new in the tumor itself. Most cases are sporadic; no clear lifestyle or environmental risk factors are known.
Genetic influences
Genetics can be important in epithelioid type angiomyolipoma, especially when it occurs with inherited tuberous sclerosis complex. Many cases are not clearly inherited, but genetic changes in tumor cells may help guide diagnosis and follow-up.
Diagnosis
Epithelioid type angiomyolipoma is usually diagnosed after a scan finds a suspicious kidney mass. Doctors confirm the diagnosis of epithelioid type angiomyolipoma by examining tissue from a biopsy or surgery, sometimes with special lab tests.
Treatment and drugs
Epithelioid type angiomyolipoma is often treated with surgery, especially if the tumor is growing or looks aggressive. Some people also need close imaging follow-up. If it has spread, targeted cancer medicines may be considered.
Symptoms
Many people with epithelioid type angiomyolipoma have no symptoms at first, and the tumor is often found during imaging for something else. When symptoms do happen, they usually relate to the kidney or nearby tissues, such as pain in the side, blood in the urine, or a mass that can be felt. The early symptoms of epithelioid type angiomyolipoma can be easy to miss because they overlap with more common kidney problems. Symptoms vary from person to person and can change over time.
Many people with epithelioid type angiomyolipoma feel well, and the growth is found by chance during an ultrasound or CT scan done for another reason. This can be true even when the tumor is fairly large.
Pain in the side, lower back, or upper belly is one of the more common symptoms. It may feel like a dull ache, pressure, or a sharper pain that does not fully go away.
You may notice urine that looks pink, red, or tea-colored, though sometimes blood is only seen on a lab test. In epithelioid type angiomyolipoma, this can happen when the tumor irritates or bleeds into the urinary tract.
Some people notice belly fullness, bloating, or a firm area in the side if the tumor becomes large. Some may find bending, lying on one side, or eating a big meal more uncomfortable than usual.
How people usually first notice Epithelioid type angiomyolipoma?
Many people first notice epithelioid type angiomyolipoma after blood in the urine, flank or belly pain, or a feeling of pressure leads to a scan, while others find out by chance when imaging is done for something else. In some cases, the first warning sign is sudden pain from bleeding inside the tumor, which needs urgent medical attention, but smaller tumors may cause no symptoms at all. Because these symptoms can overlap with common kidney problems, how epithelioid type angiomyolipoma is first noticed often comes down to imaging tests such as ultrasound, CT, or MRI rather than symptoms alone.
Types of Epithelioid type angiomyolipoma
No distinct types of epithelioid type angiomyolipoma are widely recognized.
Can I slow down the onset of symptoms?
Probably not in any proven way: for epithelioid type angiomyolipoma, a rare kidney growth, there is no strong evidence that diet, exercise, supplements, or other lifestyle changes can meaningfully delay when symptoms begin. Healthy habits like not smoking, keeping blood pressure in a healthy range, and staying active are good for overall health, but they have not been shown to prevent this growth or reliably push symptoms back; what is well established is regular follow-up with a kidney specialist and imaging when advised, so a growing growth can be treated early to lower the chance of pain or bleeding. That may reduce the risk of complications, not stop the condition from developing, but staying in care can still help you act early if changes happen.
What genetics can tell you about symptoms
Genetics can sometimes give clues, but they do not reliably predict the exact symptoms of epithelioid angiomyolipoma. Some cases are linked to changes in the TSC1 or TSC2 genes, especially in people living with tuberous sclerosis complex, and this can make tumors more likely to appear at a younger age or in more than one place, which may affect how severe symptoms become. Even so, day-to-day symptoms usually depend more on where the tumor is, how large it is, and whether it bleeds or spreads than on the specific genetic change alone.
Causes and risk factors
Epithelioid type angiomyolipoma often develops without a clear cause, and many cases seem to happen by chance. Some people have changes in the TSC1 or TSC2 genes, either inherited or new, and this is most common in those living with tuberous sclerosis complex. It is seen more often in adults and may be more common in women, so age and sex may affect the risk factors for epithelioid type angiomyolipoma. No specific food, habit, or environmental exposure has been proven to cause epithelioid type angiomyolipoma. Knowing your family history is a good first step if you are concerned about your risk.
What are the most common causes or risk factors?
The clearest known risk factor for epithelioid angiomyolipoma is tuberous sclerosis complex, an inherited condition that can cause growths in different parts of the body and is linked to changes in the TSC1 or TSC2 genes. Many people with this tumor do not have a family history, though, and it can also happen sporadically, which means by chance. It is seen mostly in adults, and some studies suggest it may be a little more common in women, but no specific lifestyle, diet, or environmental cause has been clearly proven.
Environmental and biological risk factors
Epithelioid type angiomyolipoma is a rare tumor, usually found in the kidney, and its causes are still being studied. Doctors often group risks into internal (biological) and external (environmental). When people ask about risk factors for epithelioid type angiomyolipoma, the clearest links are biological, while no specific environmental cause has been firmly proven.
People with tuberous sclerosis complex have a higher chance of kidney angiomyolipomas, and this includes the epithelioid type. This condition affects body signals that normally help keep cell growth under control.
Epithelioid type angiomyolipoma is reported more often in women than in men. This suggests sex-related body factors may influence risk, although it can still occur in either sex.
Most cases are diagnosed in adults, often during middle age rather than childhood. Age does not cause the tumor by itself, but the condition is uncommon in younger people.
Hormones may help explain why these tumors are seen more often in women and can sometimes change during pregnancy. The evidence is stronger for angiomyolipomas overall than for the epithelioid type specifically, so this is considered a possible rather than proven factor.
Genetic risk factors
Epithelioid type angiomyolipoma is most often linked to changes in genes that control cell growth, especially TSC2 and TSC1. These genes help keep a major growth pathway called mTOR under control, so when they stop working properly, cells can grow too easily. Carrying a genetic change doesn’t guarantee the condition will appear. When people ask about genetic risk factors for epithelioid type angiomyolipoma, the clearest inherited risk is tuberous sclerosis complex, while many other cases begin with gene changes found only in the tumor.
Tuberous sclerosis complex: People with tuberous sclerosis complex, often shortened to TSC, have a much higher chance of developing kidney angiomyolipomas than the general population. The epithelioid type is uncommon, but it can occur as part of this inherited condition. Because TSC can run in families, a known family history of TSC can be an important clue.
TSC2 changes: Changes in the TSC2 gene are the most common genetic finding behind angiomyolipomas and are often involved in the epithelioid type as well. When TSC2 is not working, the normal brake on cell growth is weakened.
TSC1 changes: Changes in the TSC1 gene can also lead to epithelioid type angiomyolipoma, although they are usually less common than TSC2 changes. TSC1 and TSC2 work in the same pathway, so a problem in either one can push cells to grow when they should not.
Tumor-only changes: Many living with epithelioid type angiomyolipoma do not have an inherited syndrome, and the important gene changes are found only in the tumor tissue. This means the change likely happened during life in a small group of cells and is not automatically passed on to children.
Lifestyle risk factors
Lifestyle habits do not cause epithelioid type angiomyolipoma, but they can influence bleeding risk, kidney strain, recovery, and overall health during treatment and follow-up. Because these tumors may affect the kidney and can sometimes behave aggressively, the most important lifestyle factors are those that protect renal function and reduce complications. When people ask how lifestyle affects epithelioid type angiomyolipoma, the answer is mostly about symptom control, treatment tolerance, and lowering avoidable risks rather than prevention.
Poorly controlled blood pressure can add stress to the kidneys and may complicate care if the tumor involves renal tissue. Keeping blood pressure in a healthy range through daily habits can help preserve kidney function over time.
Smoking does not cause this tumor, but it can impair blood vessel health, slow healing, and worsen outcomes around surgery or other treatment. Quitting smoking may reduce recovery problems and support overall kidney and cardiovascular health.
Heavy alcohol use can worsen dehydration, interfere with medications, and increase the chance of poor recovery if treatment is needed. Moderate or avoiding alcohol is often safer, especially when kidney function is reduced or pain medicines are being used.
Inadequate fluid intake can contribute to kidney stress and may worsen how unwell a person feels if there is pain, nausea, or reduced appetite. Steady hydration supports kidney function, although fluid goals may need to match a clinician's advice.
Risk prevention
Epithelioid type angiomyolipoma usually cannot be fully prevented, because it often develops unpredictably and may be linked to an inherited condition called tuberous sclerosis complex. In practice, prevention for epithelioid type angiomyolipoma is mainly about finding it early in people at higher risk and lowering the chance of bleeding, kidney damage, or delayed treatment. Prevention is about lowering risk, not eliminating it completely.
People with tuberous sclerosis complex or a past kidney angiomyolipoma often need regular follow-up with a kidney specialist. Imaging such as ultrasound, CT, or MRI can help spot epithelioid type angiomyolipoma earlier, sometimes before it causes pain or bleeding.
Learning the early symptoms of epithelioid type angiomyolipoma can help you seek care sooner. New flank pain, blood in the urine, a growing belly mass, or sudden severe pain should be checked promptly.
Good blood pressure control and avoiding dehydration can support kidney health if this tumor affects the kidneys. For many living with epithelioid type angiomyolipoma, this can mean staying on top of routine labs and treating other kidney problems early.
If you have epithelioid type angiomyolipoma, ask your doctor to review blood thinners, aspirin, or other medicines that may raise bleeding risk. Do not stop prescribed medication on your own, but make sure the plan fits your tumor history and overall health.
Can you prevent Epithelioid type angiomyolipoma?
No, there is no proven way to prevent epithelioid type angiomyolipoma. Many cases seem to happen without a clear cause, and some are linked to an inherited condition called tuberous sclerosis, so healthy habits do not reliably stop it from forming. If this condition runs in your family or you have tuberous sclerosis, regular medical follow-up may help find changes early, but it does not fully prevent the tumor.
Transmission
Epithelioid type angiomyolipoma is not infectious, so it cannot be passed from one person to another through touch, breathing, sex, food, or blood. For many living with epithelioid type angiomyolipoma, the tumor develops as a one-time change in cells and is not something family members can catch.
When people ask about how epithelioid type angiomyolipoma is inherited, the key point is that most cases are not directly inherited, but some happen in people with tuberous sclerosis complex, a genetic condition that can run in families. If a parent has tuberous sclerosis complex, each child has a 50% chance of inheriting that condition, which can increase the chance of developing angiomyolipomas, although not everyone will develop the epithelioid type.
When to test your genes
Consider genetic testing if you have an epithelioid angiomyolipoma at a young age, multiple kidney tumors, tumors in both kidneys, or features suggesting tuberous sclerosis complex. Testing can help clarify inherited risk, guide kidney monitoring, and in some cases shape treatment choices for you and your family.
Diagnosis
Epithelioid type angiomyolipoma is usually found after imaging is done for symptoms such as belly or side pain, blood in the urine, or a kidney mass seen by chance during a scan for something else. Because this rare tumor can look like other kidney growths, the diagnosis of epithelioid type angiomyolipoma often takes more than one step. Doctors usually combine scan results with a close look at tumor tissue to make sure the diagnosis is right.
Doctors ask about symptoms such as flank pain, blood in the urine, or a feeling of fullness in the abdomen. A detailed family and health history can help, especially if there is a history of tuberous sclerosis or other kidney tumors.
An exam may help check for abdominal tenderness, a palpable mass, or signs of bleeding. This cannot confirm epithelioid type angiomyolipoma on its own, but it helps guide the next tests.
Ultrasound, CT, and MRI are the main tests used to look at the kidney mass and see its size, shape, and blood supply. These scans also help doctors judge whether the tumor looks more like a typical angiomyolipoma, epithelioid type angiomyolipoma, or another kidney tumor.
Blood tests check kidney function and may look for anemia if bleeding is suspected. Urine tests can help confirm blood in the urine and rule out more common causes such as infection.
How is Epithelioid type angiomyolipoma diagnosed?
Epithelioid type angiomyolipoma is usually found with imaging tests such as ultrasound, CT, or MRI, often after a kidney mass is seen or symptoms like pain or bleeding lead to a scan. Because this type can look a lot like kidney cancer on imaging, doctors often confirm the diagnosis by examining a sample of the tumor under a microscope, sometimes with special lab tests that help identify the kind of cells present. Genetic testing may be discussed if there are signs of a related inherited condition called tuberous sclerosis, but the tumor itself is mainly diagnosed from the scan and the tissue results.
Stages of Epithelioid type angiomyolipoma
Epithelioid type angiomyolipoma does not have defined progression stages. This is because it is usually judged by its size, location, how it looks on scans and under the microscope, and whether it is growing or spreading, rather than by a step-by-step pattern over time. Doctors usually start with a conversation about symptoms and then use imaging tests such as ultrasound, CT, or MRI, with a biopsy or surgery sometimes needed to confirm how epithelioid type angiomyolipoma is diagnosed. Follow-up is based on individual risk, and may include repeat scans and specialist review to watch for growth, bleeding, or signs that the tumor is acting more aggressively.
Outlook and prognosis
The outlook for epithelioid type angiomyolipoma is more guarded than for classic angiomyolipoma because this variant can behave aggressively and, in some cases, act like a malignant tumor. People with small, localized tumors that can be completely removed often do well, but the risk of local recurrence or spread is higher when the tumor is large, shows marked cellular atypia, necrosis, a high mitotic rate, or extends into blood vessels or nearby tissues. Metastases most often involve the liver, lungs, or lymph nodes and may appear months to years after the initial diagnosis, so long-term follow-up is usually recommended. When an epithelioid angiomyolipoma has already spread, the prognosis is substantially worse and treatment may require systemic therapy in addition to surgery. Disease-related deaths have been reported, particularly in patients with metastatic or highly aggressive tumors, although the rarity of this condition means precise survival estimates are limited. Overall, prognosis is best when the tumor is detected early, fully excised, and lacks high-risk pathologic features.
Long-term effects
For many, the long-term picture with epithelioid type angiomyolipoma depends on the tumor’s size, how fast it grows, and whether it stays limited to one area or behaves more aggressively. Unlike the more common non-epithelioid form, this type can sometimes come back after treatment or spread, so the long-term effects of epithelioid type angiomyolipoma can be more serious for some people. Doctors may track these changes over years to see how the condition is behaving and whether kidney health is affected.
Epithelioid type angiomyolipoma can return after surgery or other treatment, especially if the original tumor was large or had more aggressive features under the microscope. For many, this means long-term follow-up scans may remain part of care for years.
If the tumor involves a large part of the kidney, some people may be left with reduced kidney function over time. This can matter more if both kidneys are affected or if a kidney has been partly or fully removed.
Some tumors can bleed into the kidney or nearby tissue, which may cause sudden pain, dizziness, or a drop in blood count. Even after treatment, people with epithelioid type angiomyolipoma may still need monitoring because bleeding can sometimes happen again.
In a smaller group of people, epithelioid type angiomyolipoma can spread beyond the kidney to places such as nearby lymph nodes, the liver, or the lungs. When this happens, the outlook is more serious and long-term treatment may be needed.
How is it to live with Epithelioid type angiomyolipoma?
Living with epithelioid angiomyolipoma can feel uncertain because many people are coping not only with symptoms, if they have any, but also with scans, follow-up visits, and the worry that this rare kidney tumor can sometimes behave more aggressively than a typical angiomyolipoma. Daily life may be affected by pain in the side or abdomen, fatigue, or limits after surgery or other treatment, while some people feel physically well and mainly carry the emotional weight of ongoing monitoring. For partners, family, and close friends, the condition often means helping with appointments, recovery, and decisions about treatment, while also sharing the stress that comes with not always knowing how the tumor will act.
Treatment and drugs
Epithelioid type angiomyolipoma is usually treated based on the tumor’s size, where it is, how fast it is growing, and whether it is causing problems such as pain, bleeding, or pressure on nearby organs. Many people with epithelioid type angiomyolipoma need close follow-up with scans over time, while others may need a procedure or surgery to remove the growth, especially if doctors are worried it could behave more aggressively than the more common form of angiomyolipoma. Doctors sometimes recommend a combination of lifestyle changes and drugs, and in some cases treatment may include medicines that target a growth pathway called mTOR, particularly when the tumor is linked to tuberous sclerosis complex or cannot be safely removed. Not every treatment works the same way for every person, so the best plan depends on your overall health, symptoms, and the results of imaging and tissue testing.
Can you cure Epithelioid type angiomyolipoma?
There is no single medicine that reliably cures epithelioid type angiomyolipoma, but some people can be cured if this rare growth is found early and completely removed with surgery. If it has spread, comes back, or cannot be fully removed, treatment usually aims to control it, slow its growth, and lower the chance of problems with surgery, procedures that block its blood supply, or sometimes cancer medicines.
Non-drug treatment
Treatment is often centered on monitoring the tumor closely or removing it when there is concern about growth, bleeding, or spread. Managing this condition often means balancing cancer control with protecting as much kidney function as possible. Because epithelioid type angiomyolipoma can behave more aggressively than the usual form of angiomyolipoma, care is usually planned with a urologist, radiologist, and pathologist working together. The best non-drug treatment for epithelioid angiomyolipoma depends on the tumor’s size, location, how fast it is changing, and whether it has features that raise concern under the microscope.
Small tumors that are not causing problems may be watched with repeat scans and checkups instead of treated right away. This can be a good fit when the mass looks stable and there are no signs of bleeding or spread. Not every approach works the same way, so the scan schedule is tailored to your situation.
Partial nephrectomy removes the tumor while leaving the rest of the kidney in place when possible. This is often preferred if the mass can be taken out safely, especially in people who may need to preserve kidney function over time.
Radical nephrectomy removes the whole kidney and may be needed if the tumor is large, deeply placed, or hard to separate from normal tissue. For many living with epithelioid type angiomyolipoma, this may be the safest option when cancer-like behavior is a concern.
This procedure blocks the blood supply feeding the tumor through a thin tube placed into a blood vessel. It can help control bleeding, shrink the mass, or lower bleeding risk before surgery. Some non-drug options are delivered by specialists with imaging guidance rather than through an operation.
Your genes may have an impact on how drugs work for you
For people living with epithelioid angiomyolipoma, treatment is often based more on the tumor’s behavior and its underlying gene changes than on symptoms alone, because some of these growths are more likely to respond to targeted medicines that slow down cell growth, while others may not. In some cases, inherited gene changes linked with related conditions can also matter, since they may make these medicines a better fit or help doctors decide how closely to watch for side effects. This kind of gene-guided treatment choice is part of what is called pharmacogenomics, but for many people, surgery and imaging follow-up still play a bigger role than gene-based drug selection.
Pharmacological treatments
When epithelioid type angiomyolipoma cannot be removed fully, has spread, or keeps coming back, doctors may use medicines that slow cell growth rather than standard cancer drugs alone. The main medicines used are mTOR inhibitors, especially everolimus, sirolimus, and in some advanced cases nab-sirolimus. Not everyone responds to the same medication in the same way. In many living with this tumor, drug treatment is mainly considered for unresectable or metastatic disease rather than for a small tumor found early.
Everolimus is an mTOR inhibitor and is one of the best-known drug options for angiomyolipoma, especially when the tumor is linked to tuberous sclerosis or cannot be treated easily with surgery. It may help shrink the tumor or slow growth, which can be important in treatment for advanced epithelioid type angiomyolipoma.
Sirolimus works on the same pathway as everolimus and may be used when doctors want another mTOR-blocking option. Dosing may be increased or lowered gradually to balance tumor control with side effects such as mouth sores, higher infection risk, or changes in cholesterol.
Nab-sirolimus is a form of sirolimus designed for intravenous treatment and is used for some people with malignant PEComa, a group of rare tumors that includes epithelioid angiomyolipoma. It is usually considered when the disease has spread or cannot be removed safely.
Standard chemotherapy has a less certain role in epithelioid type angiomyolipoma, but drugs such as doxorubicin, ifosfamide, gemcitabine, or docetaxel may be tried in selected advanced cases. If one option isn’t effective, second-line or alternative drugs may be offered, although benefit can be limited.
Genetic influences
Genetics can play an important role in epithelioid type angiomyolipoma, but not every case is inherited. In some people, it is linked to tuberous sclerosis complex, an inherited condition usually caused by changes in the TSC1 or TSC2 genes, which help keep cell growth under control. Family history is one of the strongest clues to a genetic influence, especially if relatives have tuberous sclerosis or similar kidney tumors. Many living with epithelioid type angiomyolipoma, though, have no clear family history, and the gene change may be found only in the tumor rather than in all of the body’s cells. Understanding the genetic causes of epithelioid type angiomyolipoma can help doctors decide whether genetic counseling or testing may be useful. That can be especially helpful when the tumor appears at a younger age or alongside other signs of tuberous sclerosis, such as skin changes, seizures, or multiple kidney growths.
Is Epithelioid type angiomyolipoma genetic?
Genetics can be important in epithelioid type angiomyolipoma, especially when it occurs with inherited tuberous sclerosis complex. Many cases are not clearly inherited, but genetic changes in tumor cells may help guide diagnosis and follow-up.
Having a genetic risk is not necessarily a diagnosis
Genetic variants are a usual part of being human and are widely found across the general population. Most do not have a direct impact on health and simply reflect normal human diversity. For many genes, carrying a variant associated with a condition suggests a possible link rather than a certain diagnosis, especially when more than one gene and environmental factors are involved. In some situations, though, a single well-understood variant in a particular gene can be enough to confirm the diagnosis.
Pharmacogenetics—how genetics influence drug effects
Treatment for epithelioid type angiomyolipoma is often shaped by changes in genes that control cell growth, especially TSC1 or TSC2. Variants in certain genes may switch on a growth pathway called mTOR, which is why medicines that block this pathway, such as everolimus or sirolimus, can help some people with epithelioid type angiomyolipoma, particularly when surgery is not the best option or the tumor has spread. Genetic testing for epithelioid type angiomyolipoma, or testing for an inherited condition called tuberous sclerosis complex, can sometimes help doctors decide whether these drugs are likely to make sense. Surgery is still often the main treatment, because this type can behave more aggressively than the more common form of angiomyolipoma. Not every tumor has the same genetic pattern, so treatment also depends on where the tumor is, how fast it is growing, and how well the kidney is working. For many living with epithelioid type angiomyolipoma, genetics adds one important piece of the picture rather than giving a complete answer on its own.
Interactions with other conditions
People living with epithelioid type angiomyolipoma may also need care for other kidney problems, especially if the tumor is large, affects both kidneys, or causes bleeding that lowers kidney function over time. Another important aspect is how it may link with other diseases. In some cases, epithelioid type angiomyolipoma occurs alongside tuberous sclerosis complex, an inherited condition that can cause growths in the kidneys, brain, skin, and other organs, so doctors may look for clues in your personal and family history. It can also be hard to tell apart from kidney cancer on scans or even under the microscope, which matters because the treatment plan and follow-up can be quite different. For many, this can mean extra imaging, closer monitoring, and sometimes input from both kidney and cancer specialists. If you are reading about early symptoms of epithelioid type angiomyolipoma, it is also worth knowing that sudden flank pain, blood in the urine, or a quick drop in blood pressure can signal bleeding and need urgent medical attention.
How genes can cause diseases
Humans have more than 20,000 genes, each carrying out one or a few specific functions in the body. One gene instructs the body to digest lactose from milk, another tells the body how to build strong bones and another prevents the body's cells from beginning to multiply uncontrollably and developing into cancer. As all of these genes combined are the building instructions for our body, a defect in one of these genes can have severe health consequences.
Through decades of genetic research, we know the genetic code of any healthy/functional human gene. We have also identified that in certain positions on a gene, some individuals may have a different genetic letter from the one you have. We call these hotspots "Genetic Variations" or "Variants" in short. In many cases, studies have been able to show that having the genetic letter "G" in the position makes you healthy, but having the letter "A" in the same position disrupts the gene function and causes a disease. Genopedia allows you to view these variants in genes and summarizes all that we know from scientific research, which genetic letters (Genotype) have good or bad consequences on your health or on your traits.
What other conditions can cause similar symptoms to Epithelioid type angiomyolipoma?
Other kidney problems can look a lot like epithelioid angiomyolipoma, especially kidney cancer and other kidney growths, including the more common type of angiomyolipoma. Kidney stones, kidney cysts, and sometimes kidney infections can also cause side pain, blood in the urine, or swelling in the belly, so doctors often need scans and sometimes a small tissue sample to tell them apart.
History
For many years, doctors grouped unusual kidney growths mainly by how they looked under the microscope and whether they seemed harmless or more aggressive. Some tumors did not fit neatly into those older categories. Epithelioid type angiomyolipoma gradually came into clearer focus as pathologists noticed that a small number of these growths behaved differently from the more typical angiomyolipoma that many people hear about.
First described in the medical literature as a distinct pattern within the broader angiomyolipoma family, this tumor drew attention because its cells looked more rounded and sheet-like than expected, and because some cases acted more aggressively. That mattered in real life: instead of a kidney mass being treated as a routine incidental finding on a scan done for back pain or a stone, doctors sometimes had to consider closer follow-up or surgery. Over time, reports from different centers helped show that epithelioid type angiomyolipoma is uncommon, but important to recognize because its course can vary from slow-growing to more serious.
As medical science evolved, testing methods improved and specialists became better at telling this tumor apart from other kidney masses that can look similar at first glance. Researchers later identified a genetic cause in some settings, which helped explain why epithelioid type angiomyolipoma can appear either on its own or as part of a broader medical condition, though the history of the disease was first built from careful observation rather than genetics. Not every early description was complete, yet together they helped shape the modern view that this is a rare form of angiomyolipoma with features that deserve expert review.
Today, the history of epithelioid type angiomyolipoma is still being written as more cases are studied. That ongoing work has improved how doctors interpret the early symptoms of epithelioid type angiomyolipoma, how they estimate risk, and how they plan treatment. For people living with this diagnosis, that progress means the condition is better recognized than it was in the past, and decisions are now more often guided by teams familiar with its uncommon behavior.